{"name":"Arcturus Therapeutics, Inc.","slug":"arcturus-therapeutics-inc","ticker":"","exchange":"","domain":"arcturusrx.com","description":"","hq":"San Diego","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"ARCT-021 Dose Regimen 1","genericName":"ARCT-021 Dose Regimen 1","slug":"arct-021-dose-regimen-1","indication":"Other","status":"phase_1"},{"name":"ARCT-032","genericName":"ARCT-032","slug":"arct-032","indication":"Other","status":"phase_2"},{"name":"Influenza vaccine, adjuvanted","genericName":"Influenza vaccine, adjuvanted","slug":"influenza-vaccine-adjuvanted","indication":"Influenza prevention in adults","status":"phase_3"},{"name":"ARCT-021 Dose Regimen 2","genericName":"ARCT-021 Dose Regimen 2","slug":"arct-021-dose-regimen-2","indication":"Other","status":"phase_1"},{"name":"ARCT-154","genericName":"ARCT-154","slug":"arct-154","indication":"Other","status":"phase_1"},{"name":"ARCT-165","genericName":"ARCT-165","slug":"arct-165","indication":"Other","status":"phase_1"},{"name":"ARCT-2138","genericName":"ARCT-2138","slug":"arct-2138","indication":"Other","status":"phase_1"},{"name":"ARCT-2304","genericName":"ARCT-2304","slug":"arct-2304","indication":"Other","status":"phase_1"},{"name":"Placebo booster","genericName":"Placebo booster","slug":"placebo-booster","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"ARCT-2303","genericName":"ARCT-2303","slug":"arct-2303","indication":"Pancreatic cancer (in combination with checkpoint inhibitor)","status":"phase_3"},{"name":"ARCT-810","genericName":"ARCT-810","slug":"arct-810","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ARCT-021 Dose 1","genericName":"ARCT-021 Dose 1","slug":"arct-021-dose-1","indication":"COVID-19","status":"phase_2"}]}],"pipeline":[{"name":"ARCT-021 Dose Regimen 1","genericName":"ARCT-021 Dose Regimen 1","slug":"arct-021-dose-regimen-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-032","genericName":"ARCT-032","slug":"arct-032","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Influenza vaccine, adjuvanted","genericName":"Influenza vaccine, adjuvanted","slug":"influenza-vaccine-adjuvanted","phase":"phase_3","mechanism":"An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains.","indications":["Influenza prevention in adults"],"catalyst":""},{"name":"ARCT-021 Dose 1","genericName":"ARCT-021 Dose 1","slug":"arct-021-dose-1","phase":"phase_2","mechanism":"ARCT-021 is a mRNA-based vaccine.","indications":["COVID-19"],"catalyst":""},{"name":"ARCT-021 Dose Regimen 2","genericName":"ARCT-021 Dose Regimen 2","slug":"arct-021-dose-regimen-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-154","genericName":"ARCT-154","slug":"arct-154","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-165","genericName":"ARCT-165","slug":"arct-165","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-2138","genericName":"ARCT-2138","slug":"arct-2138","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-2303","genericName":"ARCT-2303","slug":"arct-2303","phase":"phase_3","mechanism":"ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells.","indications":["Pancreatic cancer (in combination with checkpoint inhibitor)","Non-small cell lung cancer (in combination with checkpoint inhibitor)"],"catalyst":""},{"name":"ARCT-2304","genericName":"ARCT-2304","slug":"arct-2304","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-810","genericName":"ARCT-810","slug":"arct-810","phase":"phase_2","mechanism":"ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"Placebo booster","genericName":"Placebo booster","slug":"placebo-booster","phase":"phase_3","mechanism":"A placebo booster is a formulation designed to enhance the placebo effect through optimized delivery or presentation characteristics.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOd3lUZUdESFdlOXJQSGNOUGVlNldkLXhuM3lWdmY1b2p3TmYxNnp0V0VPRjV3MGxqZmhVSmtscFpFUXlYOWRFcF91QktFWk1qd3NxTE11QlQzS19JRjFLTUd5Z0pnTEUtMWV3SEwtNEQ3amx2VWVzOGx2UzdJeU11SG9oQnViQ203c2l3T2JpUW9EalNVU2tn?oc=5","date":"2026-03-03","type":"earnings","source":"Yahoo Finance","summary":"Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Yahoo Finance","headline":"Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNcWxVeGs0ZVhlaEw4bTQ2R2lLTVFwZnpoVlc3NTNwTVVEWHRmcno4c0pqeUdxbUthQUU4QzBLZGROMW5Kb3loWkI2Um40aVNnWFlQd2JZTVBleHg0U2MzandRdkdWeUhDS1N4MDVBOHpybmJlSTJraEdZVVdTUk5wYWctTkpfVThUdEFvQ1BDbXI0QUpoTUVpZ1lWTW9leng0aDRtQUNYU0lWMlVoRURyZUIzaXVZTEpqT3ZfNXgwUGhoaHNkcGc2ZUNXalozN0FJcXVsUQ?oc=5","date":"2025-12-03","type":"pipeline","source":"MarketWatch","summary":"Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch","headline":"Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOREh3QlpRZnRwQkZtLXBuaFhGT0Z2N2tpRVR1Tk44YkFKTHBDOWlCMHZaNWJZdklxWUJDaFBYRmRubldNLXBCRndIbDN0cmJmTkd5b2lpWGw3QVlFa1NmdGJocXRXQ1FwYldEUkdYZE1WNjY0eXdPZm9CNWFtejZMUER4LTlKV3dYSmFlbjRWd0t4QXY3VXdGRGxXYUhGYlpoempUUnNCUzQtbzdSMzNR?oc=5","date":"2025-10-23","type":"trial","source":"BioSpace","summary":"Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug - BioSpace","headline":"Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPNnB3MmI3SjBBb2EycV9pcVdYbUdwZTBpUV9EaUhCSkVWSjNCcWtEN0ZrX2VHS1J5cFFid1QxZUdqOWs2ZEdRMVpSa3FiZ3JDeFNLS1h3azdOaFFjcjVTS191UG5kdVlMRWdyWE5tazRNa0lhc0FHejVhNU5XcXRfTTFmd2VLdi1YV2hnRDJB?oc=5","date":"2025-10-03","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance","headline":"Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQNVFLVU44TzJqT0dld29PWEFwdFpIS3c3Sm15TkpZUGhwNHZfdFlLTWdFbmdKUnM3QzRGaTZ3ZnhDRDc5SFFKVGl4UGtLRW9tR0VuVVpieHI5OTJZRk1yVHN1bVBJOEhnRjAwSGh6X1dxWldabmFYMjgyMkZydmJqbVBMX043TjY0SHkxM3JJQy1EdXlETmpXdm9rNFQ3aXpHaEV0RElKcnRqUlF5S083dnlweUt0R3lJMElDTjl6Mk1pSmdJdUNReklnZ0dsT2VHbWZHVGRfMjFEMU1JWkZzNXVsN1d4T0ZTTHAxalFkV25TMFhpdmk1T2R30gH_AUFVX3lxTE9QUE51c0w2a0phQ2s5TVdWZmRsVVR2N2FFalo1SEpuZ3lWVlNtVmo1dndkbk5GcExGUVpEamxzVllTbVlxTndZV2tzT1dhZzhGWE9JYmlfNHdVUTJvTWg1Tm8tR0N6ZW5YYjZzZm5UMDVGTlliY3BwQ2EtN01vY2Zrb0RBSUsxSmhzREJMM1VWcXJFdTUyanMxRmFDNEpaZmY4dkJkX1EtZmFmVEZTaUFvQUNlb0EtbWQ5REtoN2FGTXZZbG55ZGRMQjlaOFdBUWZuVkczUE9tUHdCWkdBWEhJMGxhMHpSRVFPOHY3V3JWVUlfZklsdElqNkRFV3VGZw?oc=5","date":"2025-07-31","type":"pipeline","source":"simplywall.st","summary":"Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load? - simplywall.st","headline":"Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB0UzJzWWNreE9mdGo2d2UtZ3ZTUXFZNFhOaFUzdWR0VTBZV29CT05BaWNkblNkTHBHQ1NrQlN3cUhIUUZRYWNCaEJBaDZfZVZIMzZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ARCT Stock Price, News & Analysis - Stock Titan","headline":"ARCT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNYnhLNDRqdXVZUFpkeTdfektDLU9QTUpWdVpSRUlSTk9WcEdQdXMtOEVRQXFLZnpwNE4zdU0wSlptNTdEbWdzVUQtU2JOVzIwWUJINzhUQlNublQ4aTJnSGVKZ2loQVBQRVA0bktIWkMxMVA2Y1dVTnRsSXRWeGlKdXdmN2Y1WU1tVnlHOW83WTlIZUIybk1HZExoU3BaYmNHR041a2VyOWlaOGQzNnV1MWZoTnpvY0NFMDFMd2JQeDU3cE9jc3FzQWh0Q3RxZDg3YmE5TG5iZEo4b0hlWERmSk1wd3lPaWpxSDlVX25NNU44dTBCanlSZUg3ekJOZG9KT3pEb0V2ZF9ncDA3NUI1MER0MFRTQzBuY3J5aVh1bGVBVk9VREQwVTJ3?oc=5","date":"2025-04-10","type":"regulatory","source":"Business Wire","summary":"Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire","headline":"Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pande","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-09-13","type":"regulatory","source":"PR Newswire","summary":"Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Me","headline":"Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1DalltVXBaWHY1dnNnWi02Yk8wR2dfcksyQzdkcVBienJZbzlmQ092ZnFZV05yd0VOMVhXMlpaV25LdVJ2dHdsR2RHc05Lal8yYVh0dm51bFg3QnJhVDNsd3lkb1IxWGR5LVRjendnLURtZHNjeFBGcw?oc=5","date":"2022-06-09","type":"pipeline","source":"jetro.go.jp","summary":"Arcturus Therapeutics, a U.S. developer of mRNA medicines, has established a Japanese subsidiary in Chiba Prefecture as a joint venture with Axcelead, Inc., and is setting up a manufacturing plant in ","headline":"Arcturus Therapeutics, a U.S. developer of mRNA medicines, has established a Japanese subsidiary in Chiba Prefecture as ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNdV90V2lKNWVNckhLTUhiblRkYWhWWm1mcWdhS3Byc3JaZkNOUlg5ZGRCQlZvTExFNi13ZU53cWlaMjdSM1FiTkVSRkJ3U3A3Z25rRXNRSHVqZE9MZVNxckJxcVJYVlV3NEVpMlFqRTZVR1dmRFNwbEpKcHhVMV9nNUZlNnpRd2tMXzh2MXh5bk5Uc0xhMVVvU2ZCOUxobW85OXpscTZBeHJaNXRZdTBYQTJPYTVnMUVGcEJvcUVDbm1mRGNHLURYZ01FbTFRUHVnSVo4RHUzakNvSmhCSXI0Y1hHMHRhYUNkX0RpTzh6dWFNbTEzVjZBQVpwRHh6dzA?oc=5","date":"2020-05-04","type":"deal","source":"GlobeNewswire","summary":"Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine - GlobeNewswire","headline":"Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPcHRjSUFfRU5VOWh0ZXNqQXBaaTlyRml4NEFUYXFVNWRRZVRmWjR6LVlGMmp5ZjZRWGtxQl9MdEN4SFYwVUxqUHlHZEdyU2hyTWxKc2V2ZU5DUFlEUGduSFl0OXBuSEtBeDFlckw0SFNVVXdXemwyRFFfVDJYdkNmWWFiRVhtdTNxNzB3azQ0emt6bzlLc1RZ?oc=5","date":"2017-09-29","type":"deal","source":"BioPharma Dive","summary":"Arcturus to go public through merger with Alcobra - BioPharma Dive","headline":"Arcturus to go public through merger with Alcobra","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_1":6,"phase_2":3,"phase_3":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}